Top Story

Ohr releases new interim data on Squalamine eye drops

August 20, 2014

Ohr Pharmaceuticals reported additional interim data from its phase 2 study on Squalamine eye drops for the treatment of wet age-related macular degeneration.

Data showed eyes that received a combination of Squalamine eye drops (OHR-102) and as-needed dosing of Lucentis (ranibizumab, Genentech) had visual acuity and anatomical benefits compared with patients who received placebo eye drops in combination with as-needed dosing of ranibizumab. Jason S. Slakter, MD, chief medical officer of Ohr, presented the new interim data at the American Society of Retina Specialists annual meeting.

Meeting News CoverageVideo

PLANET study shows differences in pain from intravitreal injections

August 20, 2014
At the American Society of Retina Specialists meeting in San Diego, Arshad Khanani, MD, discusses his presentation of the PLANET study, which compared pain and…
Perspectives on Glaucoma

Study: Glaucoma patients have lower reading ability, engagement

August 19, 2014
Patients with glaucoma read less and have a lesser reading ability, according to a study recently published in Investigative Ophthalmology & Visual Science.As…

PhysIOL, Carl Zeiss Meditec settle legal dispute over trifocal IOLs

August 19, 2014
PhysIOL and Carl Zeiss Meditec have reached an out-of-court settlement of a legal dispute about patents and utility models for trifocal IOLs, according to a press…
More News Headlines »
In the Journals

Fundus autofluorescence imaging useful in identifying AMD patterns, study finds

August 18, 2014
Specific fundus autofluorescence patterns are associated with choroidal neovascularization development, according to a…
More »
Blog

Managing hypertension as an optometric physician

July 8, 2014
For many of us who began our optometric careers in the days before therapeutic drug laws, the idea of managing a…
More »
Meeting News Coverage Video
figure

VIDEO: OCT, FAF diagnoses peripapillary retinal pigmentary degeneration

May 13, 2014
More »